Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating

What: Tarsus Pharmaceuticals' stock has earned an upgrade to its Relative Strength (RS) rating.
Why: The upgrade is attributed to its 69% gain in the last 52 weeks, outperforming 96% of stocks.
Signal: The RS rating upgrade indicates a strong price performance over the past year.
Target: The stock's RS rating is now at **85**, indicating a strong upward trend.
Risk: Investors should be aware that the stock's price may be volatile, with a beta of **1.43**.